구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Magrolimab |
Overview Company | Gilead Sciences |
Overview Modality | ANTIBODY |
Overview Target | Multiple Myeloma |
Overview Indication | Solid Tumor; Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Half-life | 13 h |
Toxicology Major finding | Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma.. The phase II ELEVATE HNSCC study evaluated magrolimab combinations in metastatic head and neck squamous-cell carcinoma (mHNSCC). Eligible patients had previously untreated recurrent/mHNSCC (untreated cohort) or pretreated advanced/mHNSCC (pretreated cohort). Safety run-in (SRI) evaluations w… |
Clinical Safety signal | Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma.. The phase II ELEVATE HNSCC study evaluated magrolimab combinations in metastatic head and neck squamous-cell carcinoma (mHNSCC). Eligible patients had previously untreated recurrent/mHNSCC (untreated cohort) or pretreated advanced/mHNSCC (pretreated cohort). Safety run-in (SRI) evaluations w… |
Clinical Selected reported efficacy | ORR 37.7% |
Clinical Reported ORR | 37.7% |
Clinical Result source | ClinicalTrials.gov NCT04313881 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT04313881 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Magrolimab |
Overview Company | Gilead Sciences |
Overview Modality | ANTIBODY |
Overview Target | Multiple Myeloma |
Overview Indication | Solid Tumor; Colorectal Cancer |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Half-life | 13 h |
Toxicology Major finding | Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma.. The phase II ELEVATE HNSCC study evaluated magrolimab combinations in metastatic head and neck squamous-cell carcinoma (mHNSCC). Eligible patients had previously untreated recurrent/mHNSCC (untreated cohort) or pretreated advanced/mHNSCC (pretreated cohort). Safety run-in (SRI) evaluations w… |
Clinical Safety signal | Phase II study of magrolimab combination therapies in patients with head and neck squamous-cell carcinoma.. The phase II ELEVATE HNSCC study evaluated magrolimab combinations in metastatic head and neck squamous-cell carcinoma (mHNSCC). Eligible patients had previously untreated recurrent/mHNSCC (untreated cohort) or pretreated advanced/mHNSCC (pretreated cohort). Safety run-in (SRI) evaluations w… |
Clinical Selected reported efficacy | ORR 37.7% |
Clinical Reported ORR | 37.7% |
Clinical Result source | ClinicalTrials.gov NCT04313881 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT04313881 |
추천 비교
추천 비교